CAMBRIDGE, Mass., May 1, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in May:
- Cancer Advance NY at Apella Event Space in New York on Wednesday, May 14 at 1:00 p.m. ET, discussing protein methyltransferase inhibitors as cancer therapeutics.
- UBS Global Healthcare Conference at the Sheraton New York Hotel in New York on Wednesday, May 21 at 10:00 a.m. ET. A live webcast will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
SOURCE Epizyme, Inc.